Gewinnerbranchen der Jahre 2006 bis 2040 (Seite 902)
eröffnet am 10.12.06 16:57:17 von
neuester Beitrag 16.02.24 09:33:08 von
neuester Beitrag 16.02.24 09:33:08 von
Beiträge: 94.068
ID: 1.099.361
ID: 1.099.361
Aufrufe heute: 11
Gesamt: 3.536.002
Gesamt: 3.536.002
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 7624 | |
| vor 1 Stunde | 6034 | |
| heute 18:07 | 2987 | |
| vor 1 Stunde | 2909 | |
| gestern 18:44 | 2350 | |
| vor 1 Stunde | 2290 | |
| heute 17:49 | 1835 | |
| vor 52 Minuten | 1823 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.028,25 | +0,50 | 241 | |||
| 2. | 2. | 168,78 | +0,43 | 100 | |||
| 3. | 3. | 9,7000 | +12,27 | 81 | |||
| 4. | 14. | 6,1800 | -0,71 | 74 | |||
| 5. | 7. | 0,9850 | -1,50 | 51 | |||
| 6. | 11. | 0,1835 | -1,61 | 49 | |||
| 7. | 12. | 0,1590 | +4,88 | 49 | |||
| 8. | 24. | 60,75 | -2,71 | 37 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 59.952.616 von clearasil am 25.02.19 06:32:39Spannend ohne Zweifel, aber das ist noch ein Stück Weg bis das "Zeugs" in die Schleimhäute des Menschen kommt. Das sieht eher aus wie ein Spezialmittel als der Ersatz von Cortison in der Asthmatherapie.
Ähnlich wie mein "Demenz"-Aktie noch weit weg vom klinischen Alltag
Ähnlich wie mein "Demenz"-Aktie noch weit weg vom klinischen Alltag
Antwort auf Beitrag Nr.: 59.957.866 von haowenshan am 25.02.19 16:36:09Kurzer Hinweis: BSTI hat seit einer Woche neue NASDAQ-Kürzel: BEST
2 Ideen zu e-commerce (2. Reihe China):
bzun (ähnlich zu shopify)
&
bsti (logistik)
(es existiert zu beiden Unternehmen ein thread; falls Kürzel nicht bekannt, einfach nur googeln...)
bzun (ähnlich zu shopify)
&
bsti (logistik)
(es existiert zu beiden Unternehmen ein thread; falls Kürzel nicht bekannt, einfach nur googeln...)
zu MRKR - neue Studienergebnisse.
"We continue to be highly encouraged by the clinical results we've seen to date with our MultiTAA therapies. In AML, we believe we are seeing increasing evidence of meaningful therapeutic benefit for patients with limited treatment alternatives. Our MultiTAA therapy appears to be safe and well-tolerated with the potential to mediate a meaningful anti-tumor effect, in addition to demonstrating a compelling correlation between therapeutic responses, with superior in vivo expansion of our T cells," said Peter L. Hoang, President & CEO of Marker Therapeutics. "Similarly, the studies ongoing in acute lymphoblastic leukemia, or ALL, lymphoma and multiple myeloma continue to demonstrate positive results, and are supportive of the data we presented at ASH in December, importantly with no additional disease relapses. Overall, this data update and our update at ASH 2018 in December collectively have increased our total reported number of patients to 78 as compared to the 57 patients we had reported as of November."
AML Study Results
In Arm A of the AML study, 13 patients at Baylor College of Medicine were dosed with MultiTAA T cells as a maintenance therapy after receiving allogeneic stem cell transplant. Results demonstrated:
11 out of 13 patients remain alive, ranging from 6 weeks to 2.5 years post-infusion. Nine of these patients have never relapsed after MultiTAA therapy and continue to remain in complete remission (CR), durable between 6 weeks to 2.5 years;
Two patients saw local relapse in the central nervous system, but in both cases these patients were successfully treated with local therapy alone;
One patient saw extramedullary relapse and was subsequently treated in the active disease arm (Arm B) of the trial, generating a CR that was durable for 13 months; and
One patient relapsed 8 months after receiving MultiTAA T cells but following a second allogeneic stem cell transplant this patient remains alive in relapse 1.5 years following his initial T cell infusion.
In Arm B of the AML study, 6 patients suffering from active disease with relapsed/refractory (r/r) AML have been treated, with 1 patient having been treated twice for active disease with MultiTAA T cells;
2 patients were non-responsive to MultiTAA therapy and progressed with r/r disease;
1 patient developed a complete response (CR), which was durable for 13 months; and
1 patient developed a partial response (PR) that enabled that patient to receive a second allogeneic stem cell transplant;
The patient who developed a partial response saw significant tumor debulking, with circulating blasts reduced from over 50% to 15%.
2 additional patients who did not meet partial response criteria experienced disease stabilization enabling a 2-month delay to next-line therapy
Of these patients with disease stability, one patient was sufficiently stabilized to enable that patient to receive a second allogeneic stem cell transplant. The second transplant eliminated the patient's MultiTAA T cells. This patient was given a second dose of MultiTAA T cells after initial disease relapse after the second transplant, but progressed to another line of therapy prior to any evaluable response assessment to the subsequent dose of MultiTAA T cells;
The other patient who had disease stability saw significant reduction in tumor burden, with a reduction in circulating blasts from 70% prior to infusion of MultiTAA T cells, to approximately 45% circulating blasts after MultiTAA therapy.
For patients in Arm B, overall survival ranged from 4 to 21 months after T cell infusions.
ALL Results
In addition to data from ongoing lymphoma and multiple myeloma trials, also presented in an oral presentation at the meeting were updated results from an ongoing study in ALL. Updates from this trial included:
Patients are now up to 28 months in CCR (Continued Complete Remission);
The only patient who has experienced relapse was a patient who displayed mixed donor/recipient chimerism after transplant, but remained in CCR for 6 months prior to relapse;
Patients that remain in CCR have been durable for between 4 to 28 months, with a median duration of 16 months.
"We are very excited about the results we are seeing in our early clinical trials. For patients with r/r AML, we believe that MultiTAA therapies may produce meaningful improvements in overall survival of patients who historically have had a dire prognostic outlook," stated Mythili Koneru, Senior Vice President of Clinical Development at Marker Therapeutics. "In adjuvant settings for patients currently in remission, I believe our early clinical results suggest that we may be providing significant additional protection against relapse and disease recurrence."
"We continue to be highly encouraged by the clinical results we've seen to date with our MultiTAA therapies. In AML, we believe we are seeing increasing evidence of meaningful therapeutic benefit for patients with limited treatment alternatives. Our MultiTAA therapy appears to be safe and well-tolerated with the potential to mediate a meaningful anti-tumor effect, in addition to demonstrating a compelling correlation between therapeutic responses, with superior in vivo expansion of our T cells," said Peter L. Hoang, President & CEO of Marker Therapeutics. "Similarly, the studies ongoing in acute lymphoblastic leukemia, or ALL, lymphoma and multiple myeloma continue to demonstrate positive results, and are supportive of the data we presented at ASH in December, importantly with no additional disease relapses. Overall, this data update and our update at ASH 2018 in December collectively have increased our total reported number of patients to 78 as compared to the 57 patients we had reported as of November."
AML Study Results
In Arm A of the AML study, 13 patients at Baylor College of Medicine were dosed with MultiTAA T cells as a maintenance therapy after receiving allogeneic stem cell transplant. Results demonstrated:
11 out of 13 patients remain alive, ranging from 6 weeks to 2.5 years post-infusion. Nine of these patients have never relapsed after MultiTAA therapy and continue to remain in complete remission (CR), durable between 6 weeks to 2.5 years;
Two patients saw local relapse in the central nervous system, but in both cases these patients were successfully treated with local therapy alone;
One patient saw extramedullary relapse and was subsequently treated in the active disease arm (Arm B) of the trial, generating a CR that was durable for 13 months; and
One patient relapsed 8 months after receiving MultiTAA T cells but following a second allogeneic stem cell transplant this patient remains alive in relapse 1.5 years following his initial T cell infusion.
In Arm B of the AML study, 6 patients suffering from active disease with relapsed/refractory (r/r) AML have been treated, with 1 patient having been treated twice for active disease with MultiTAA T cells;
2 patients were non-responsive to MultiTAA therapy and progressed with r/r disease;
1 patient developed a complete response (CR), which was durable for 13 months; and
1 patient developed a partial response (PR) that enabled that patient to receive a second allogeneic stem cell transplant;
The patient who developed a partial response saw significant tumor debulking, with circulating blasts reduced from over 50% to 15%.
2 additional patients who did not meet partial response criteria experienced disease stabilization enabling a 2-month delay to next-line therapy
Of these patients with disease stability, one patient was sufficiently stabilized to enable that patient to receive a second allogeneic stem cell transplant. The second transplant eliminated the patient's MultiTAA T cells. This patient was given a second dose of MultiTAA T cells after initial disease relapse after the second transplant, but progressed to another line of therapy prior to any evaluable response assessment to the subsequent dose of MultiTAA T cells;
The other patient who had disease stability saw significant reduction in tumor burden, with a reduction in circulating blasts from 70% prior to infusion of MultiTAA T cells, to approximately 45% circulating blasts after MultiTAA therapy.
For patients in Arm B, overall survival ranged from 4 to 21 months after T cell infusions.
ALL Results
In addition to data from ongoing lymphoma and multiple myeloma trials, also presented in an oral presentation at the meeting were updated results from an ongoing study in ALL. Updates from this trial included:
Patients are now up to 28 months in CCR (Continued Complete Remission);
The only patient who has experienced relapse was a patient who displayed mixed donor/recipient chimerism after transplant, but remained in CCR for 6 months prior to relapse;
Patients that remain in CCR have been durable for between 4 to 28 months, with a median duration of 16 months.
"We are very excited about the results we are seeing in our early clinical trials. For patients with r/r AML, we believe that MultiTAA therapies may produce meaningful improvements in overall survival of patients who historically have had a dire prognostic outlook," stated Mythili Koneru, Senior Vice President of Clinical Development at Marker Therapeutics. "In adjuvant settings for patients currently in remission, I believe our early clinical results suggest that we may be providing significant additional protection against relapse and disease recurrence."
zu ASX:CYP news zu Asthma-pre-clinics und ein sehr gutes posting bezgl. der grundlegenden Technologie.
hier ein post von ZolRab zur Technologie https://hotcopper.com.au/posts/37388025/single
+++ Not sure how up to speed you are on the tech, but as Sector has mentioned, all other… literally all other Mesenchymal Cell techs, globally, are first-generation. They have to derive their cells from continuous donations, whether it be bone-marrow or placenta etc, and extensively expand them in culture to create enough cells. The main problem is senescence. When cells get divided/expanded too many times, they lose their puff, hence the reason for needing a continuous supply of donor cells. The next problem is batch to batch consistency… one donors cells are different to another, and each batch needs to be screened for safety… its a bloody headache. This is why our technology is so groundbreaking. We derive our cells from Induced Pluripotent Stem Cells. These cells can be virtually infinitely expanded without losing their puff. Then, to put it simply, the Cymerus tech can then differentiate those IPSC’s into the all important therapeutic Mesenchymal Cells. Cymerus has the only patents for this process, globally. All the cells we will ever need, from one donor! No ethical issues, no more human donations, just infinite expansion of the same consistent cell lineage. Quick read to understand IPSC’s - https://www.nature.com/news/how-ips-cells-changed-the-world-…
Prof Shinya Yamanaka won a Nobel Prize in 2012 for discovery IPSC’s (the reprogramming of human cells into an embryonic state). He’s the chap that licensed his discovery to Cellular Dynamics International, with his IPSC cell line. https://fujifilmcdi.com/news-events/news-item/cellular-dynam…
Dr James Thompson, best known for deriving the first human embryonic stem cell line in 1998 and for deriving human induced pluripotent stem cells (IPSCs) in 2007 (even though he also discovered IPSCs in 2007, Yamanaka beat him to the punch and took the Nobel Prize… such is life), is the man who founded Cellular Dynamics International.
Now here’s where it gets really exciting….
One of the Co-Founders of Cellular Dynamics International is Dr Igor Sluvkin. Sluvkin is the guy that created Cynata’s technology (Cymerus) at the Uni of Wisconsin Madison. CDI is now a Fujifilm company, acquired for USD 307m - https://xconomy.com/wisconsin/2015/04/09/the-story-behind-ce…
CDI...Fujifilm…Cynata = IPSC-derived MSC’s
It’s all the same egg-head cell biologists (the best of the best) slowly working together to bring their IPSC-derived MSC technology to the market via Cynata. That is why this technology is worth billions. The only technology in the world that can produce MSCs on a truly commercial scale.
Outstanding Phase 1 results for GvHD
3 Phase 2’s lined up for this year - GvHD CLI & OA
Fujifilm to step up shortly.
Tightly held register. +++
weiterer post von pfeiffer1982:
+++
(Early Online Access)
Abstract
The airway remodeling (AWR) associated with chronic allergic airways disease (AAD)/asthma contributes to irreversible airway obstruction. This study compared and combined the antiremodeling and other effects of induced pluripotent stem cell and mesenchymoangioblast–derived mesenchymal stem cells (MCA-MSCs) with the corticosteroid dexamethasone (Dex) in experimental chronic AAD/asthma. Female BALB/c mice subjected to 11 wk of ovalbumin (Ova)-induced chronic AAD were intranasally administered MCA-MSCs (1 × 106 cells/mouse; once weekly on wk 10 and 11), Dex (0.5 mg/ml; once daily for 2 wk), or both combined. MCA-MSC detection and changes in airway inflammation (AI), AWR, and airway hyperresponsiveness (AHR) were measured at the end of wk 11. Mice with chronic AAD had significant AI, goblet cell metaplasia, epithelial damage/thickening, aberrant TGF-β1 levels, subepithelial myofibroblast accumulation, airway/lung fibrosis, and AHR (all P < 0.001 vs. healthy controls). MCA-MSCs were detected in the lungs up to 5–7 d postadministration and demonstrated modest anti-inflammatory but striking antifibrotic effects against Ova-induced AAD, effectively decreasing AHR by 70–75% (all P < 0.05 vs. Ova alone). In comparison, Dex predominantly demonstrated anti-inflammatory effects, decreasing AHR by ∼30%. Combining MCA-MSCs with Dex provided equivalent protection to that offered by either therapy alone. MCA-MSCs reduce chronic AAD-induced AWR and AHR to a greater extent than Dex and may act as a suitable adjunct therapy to corticosteroid treatment of asthma.
https://www.fasebj.org/doi/abs/10.1096/fj.201802307R?journal…" target="_blank" rel="nofollow ugc noopener">
https://www.fasebj.org/doi/abs/10.1096/fj.201802307R?journal…
hier links:
https://hotcopper.com.au/posts/37535756/single" target="_blank" rel="nofollow ugc noopener">
https://hotcopper.com.au/posts/37535756/single
https://hotcopper.com.au/posts/37536954/single" target="_blank" rel="nofollow ugc noopener">
https://hotcopper.com.au/posts/37536954/single
hier der link zur cynata-veröfentlichung:
https://hotcopper.com.au/threads/further-cynata-asthma-study…" target="_blank" rel="nofollow ugc noopener">
https://hotcopper.com.au/threads/further-cynata-asthma-study…
hier ein post von ZolRab zur Technologie https://hotcopper.com.au/posts/37388025/single
+++ Not sure how up to speed you are on the tech, but as Sector has mentioned, all other… literally all other Mesenchymal Cell techs, globally, are first-generation. They have to derive their cells from continuous donations, whether it be bone-marrow or placenta etc, and extensively expand them in culture to create enough cells. The main problem is senescence. When cells get divided/expanded too many times, they lose their puff, hence the reason for needing a continuous supply of donor cells. The next problem is batch to batch consistency… one donors cells are different to another, and each batch needs to be screened for safety… its a bloody headache. This is why our technology is so groundbreaking. We derive our cells from Induced Pluripotent Stem Cells. These cells can be virtually infinitely expanded without losing their puff. Then, to put it simply, the Cymerus tech can then differentiate those IPSC’s into the all important therapeutic Mesenchymal Cells. Cymerus has the only patents for this process, globally. All the cells we will ever need, from one donor! No ethical issues, no more human donations, just infinite expansion of the same consistent cell lineage. Quick read to understand IPSC’s - https://www.nature.com/news/how-ips-cells-changed-the-world-…
Prof Shinya Yamanaka won a Nobel Prize in 2012 for discovery IPSC’s (the reprogramming of human cells into an embryonic state). He’s the chap that licensed his discovery to Cellular Dynamics International, with his IPSC cell line. https://fujifilmcdi.com/news-events/news-item/cellular-dynam…
Dr James Thompson, best known for deriving the first human embryonic stem cell line in 1998 and for deriving human induced pluripotent stem cells (IPSCs) in 2007 (even though he also discovered IPSCs in 2007, Yamanaka beat him to the punch and took the Nobel Prize… such is life), is the man who founded Cellular Dynamics International.
Now here’s where it gets really exciting….
One of the Co-Founders of Cellular Dynamics International is Dr Igor Sluvkin. Sluvkin is the guy that created Cynata’s technology (Cymerus) at the Uni of Wisconsin Madison. CDI is now a Fujifilm company, acquired for USD 307m - https://xconomy.com/wisconsin/2015/04/09/the-story-behind-ce…
CDI...Fujifilm…Cynata = IPSC-derived MSC’s
It’s all the same egg-head cell biologists (the best of the best) slowly working together to bring their IPSC-derived MSC technology to the market via Cynata. That is why this technology is worth billions. The only technology in the world that can produce MSCs on a truly commercial scale.
Outstanding Phase 1 results for GvHD
3 Phase 2’s lined up for this year - GvHD CLI & OA
Fujifilm to step up shortly.
Tightly held register. +++
weiterer post von pfeiffer1982:
+++
(Early Online Access)
Abstract
The airway remodeling (AWR) associated with chronic allergic airways disease (AAD)/asthma contributes to irreversible airway obstruction. This study compared and combined the antiremodeling and other effects of induced pluripotent stem cell and mesenchymoangioblast–derived mesenchymal stem cells (MCA-MSCs) with the corticosteroid dexamethasone (Dex) in experimental chronic AAD/asthma. Female BALB/c mice subjected to 11 wk of ovalbumin (Ova)-induced chronic AAD were intranasally administered MCA-MSCs (1 × 106 cells/mouse; once weekly on wk 10 and 11), Dex (0.5 mg/ml; once daily for 2 wk), or both combined. MCA-MSC detection and changes in airway inflammation (AI), AWR, and airway hyperresponsiveness (AHR) were measured at the end of wk 11. Mice with chronic AAD had significant AI, goblet cell metaplasia, epithelial damage/thickening, aberrant TGF-β1 levels, subepithelial myofibroblast accumulation, airway/lung fibrosis, and AHR (all P < 0.001 vs. healthy controls). MCA-MSCs were detected in the lungs up to 5–7 d postadministration and demonstrated modest anti-inflammatory but striking antifibrotic effects against Ova-induced AAD, effectively decreasing AHR by 70–75% (all P < 0.05 vs. Ova alone). In comparison, Dex predominantly demonstrated anti-inflammatory effects, decreasing AHR by ∼30%. Combining MCA-MSCs with Dex provided equivalent protection to that offered by either therapy alone. MCA-MSCs reduce chronic AAD-induced AWR and AHR to a greater extent than Dex and may act as a suitable adjunct therapy to corticosteroid treatment of asthma.
https://www.fasebj.org/doi/abs/10.1096/fj.201802307R?journal…" target="_blank" rel="nofollow ugc noopener">
https://www.fasebj.org/doi/abs/10.1096/fj.201802307R?journal…
hier links:
https://hotcopper.com.au/posts/37535756/single" target="_blank" rel="nofollow ugc noopener">
https://hotcopper.com.au/posts/37535756/single
https://hotcopper.com.au/posts/37536954/single" target="_blank" rel="nofollow ugc noopener">
https://hotcopper.com.au/posts/37536954/single
hier der link zur cynata-veröfentlichung:
https://hotcopper.com.au/threads/further-cynata-asthma-study…" target="_blank" rel="nofollow ugc noopener">
https://hotcopper.com.au/threads/further-cynata-asthma-study…
Trading Spotlight
Antwort auf Beitrag Nr.: 59.945.917 von Algol am 23.02.19 08:46:34
Welche Themen und Anbieter im B2B und B2C Markt sind sehr: ?
Der Onlinehandel wird sich weiter entwickeln und unterschiedliche Lösungen anbieten:
Unterscheid Amazon versus Alibaba
Alibaba-Chef Jack Ma treibt seinen Angriff auf den globalen Onlinehandel voran
https://www.handelsblatt.com/unternehmen/handel-konsumgueter…
Dies gilt auch für das B2B Geschäft in vielen Branchen Chemie, Pharma, Maschinenbau usw...
Themenfelder: kundenzentrische Plattformen früher als CRM Lösungen bekannt mit unterschiedlicher Aufgabenstellung und Technologie.
Anbieter: SAP, MSFT, Zendesk, CRM, Oracle usw..
Neue Themen in diesem Zusammenhang:
Mobile Unterstützung von kundenzentrisches Plattformen
CRM und KI konkret — Machine Learning
Die Hyper-Individualisierung, auch „tiefe Personalisierung“ genannt, umfasst die Erfahrung, die der Kunde durch Service oder Kontakt mit einem Unternehmen macht. Der Kunde erwartet nicht nur das für ihn richtige Produkt zu erhalten, sondern ein „rund-um-sorglos-Paket“.
Veränderung von Kauf zur Miete und Abomodell Charakter dadurch verändern sich Abrechungsmodelle und Bezahlungsmethoden ....
Anbieter von Subskription Modelle z.b. Anbieter wie Zuora
Digitales Marketing und CRM
IOT Internet of Things und CRM
https://emea.nttdata.com/blog/de/2018/02/21/iot-und-crm/
https://uk.pcmag.com/gallery/119262/8-iot-trends-to-anticipa…
Hier gibt es viele Optionen des Invests .....
Zur Zeit im Depot 2019
B:C Alibaba
B:B SAP und Zendesk
Darum Growth und Tech Titel weiter laufen wie MSFT, Adobe, CRM, Workaday, Oracle, ...Autodesk, Dassault usw...
Was machen die Mittelgroßen Unternehmen der Szene .... TTD, Service Now, New Relic, Twillio, VEEV,
Einige Unternehmen der genannten haben eine guten Branchenfokus gesichert, den man nicht unterschätzen sollte z.b. VEEV
Eine spanende Frage wird sein, wie diese genannten Unternehmen im B2B damit umgehen Branchenkokus versus übergreifender Anbieter zu sein !
Es gibt viele sehr gute Unternehmen in den einzelnen Segmenten, die diesen Weg der Realisierung der Digitalisierung viel Geld verdienen werden und sehr gute Invests für die Zeit bis 2030 sind.
Oberkassel
The future
Ja keine Frage die Growth Werte werden weiter gut laufen. Der Anbieter von Digitalisierungslösungen werden weiter stark angefragt werden, hier stehen wir am Anfang der Entwicklung.Welche Themen und Anbieter im B2B und B2C Markt sind sehr: ?
Der Onlinehandel wird sich weiter entwickeln und unterschiedliche Lösungen anbieten:
Unterscheid Amazon versus Alibaba
Alibaba-Chef Jack Ma treibt seinen Angriff auf den globalen Onlinehandel voran
https://www.handelsblatt.com/unternehmen/handel-konsumgueter…
Dies gilt auch für das B2B Geschäft in vielen Branchen Chemie, Pharma, Maschinenbau usw...
Themenfelder: kundenzentrische Plattformen früher als CRM Lösungen bekannt mit unterschiedlicher Aufgabenstellung und Technologie.
Anbieter: SAP, MSFT, Zendesk, CRM, Oracle usw..
Neue Themen in diesem Zusammenhang:
Mobile Unterstützung von kundenzentrisches Plattformen
CRM und KI konkret — Machine Learning
Die Hyper-Individualisierung, auch „tiefe Personalisierung“ genannt, umfasst die Erfahrung, die der Kunde durch Service oder Kontakt mit einem Unternehmen macht. Der Kunde erwartet nicht nur das für ihn richtige Produkt zu erhalten, sondern ein „rund-um-sorglos-Paket“.
Veränderung von Kauf zur Miete und Abomodell Charakter dadurch verändern sich Abrechungsmodelle und Bezahlungsmethoden ....
Anbieter von Subskription Modelle z.b. Anbieter wie Zuora
Digitales Marketing und CRM
IOT Internet of Things und CRM
https://emea.nttdata.com/blog/de/2018/02/21/iot-und-crm/
https://uk.pcmag.com/gallery/119262/8-iot-trends-to-anticipa…
Hier gibt es viele Optionen des Invests .....
Zur Zeit im Depot 2019
B:C Alibaba
B:B SAP und Zendesk
Darum Growth und Tech Titel weiter laufen wie MSFT, Adobe, CRM, Workaday, Oracle, ...Autodesk, Dassault usw...
Was machen die Mittelgroßen Unternehmen der Szene .... TTD, Service Now, New Relic, Twillio, VEEV,
Einige Unternehmen der genannten haben eine guten Branchenfokus gesichert, den man nicht unterschätzen sollte z.b. VEEV
Eine spanende Frage wird sein, wie diese genannten Unternehmen im B2B damit umgehen Branchenkokus versus übergreifender Anbieter zu sein !
Es gibt viele sehr gute Unternehmen in den einzelnen Segmenten, die diesen Weg der Realisierung der Digitalisierung viel Geld verdienen werden und sehr gute Invests für die Zeit bis 2030 sind.
Oberkassel
Nachdem 2018 kein gutes Jahr für Growth Anleger (also auch mich) war (man muss dann übrigens nicht an seinen Positionen "kleben", sondern kann jederzeit teil umschichten in Dividendenwerte, lame ducks, Shorts, Gold, cash, Anleihen etc. und auf die Art abmildern, die Performance verbessern), läuft es momentan (und imho unterm Strich und langfristig sowieso) wieder besser.
Gestern zB bei TTD:
https://www.fool.com/investing/2019/02/22/5-reasons-the-trad…
Gestern zB bei TTD:
https://www.fool.com/investing/2019/02/22/5-reasons-the-trad…
Antwort auf Beitrag Nr.: 59.943.257 von linkshaender am 22.02.19 17:17:07Hallo,
Alles gut, vollkommen in Ordnung.
Nur, Was Das nur heissen sollte: Da "einfach mal in Die Runde" zu fragen tut "nicht weh".
Also man kann Nichts dabei verlieren.
Maximal dass Nichts dabei herauskommt.
In Anderen Fällen ist man vielleicht noch ein mini Stück schlauer geworden.
Gruss
Alles gut, vollkommen in Ordnung.
Nur, Was Das nur heissen sollte: Da "einfach mal in Die Runde" zu fragen tut "nicht weh".
Also man kann Nichts dabei verlieren.
Maximal dass Nichts dabei herauskommt.
In Anderen Fällen ist man vielleicht noch ein mini Stück schlauer geworden.
Gruss
Antwort auf Beitrag Nr.: 59.938.100 von Popeye82 am 22.02.19 00:33:25Lieber Philspinacia,
AEZS war für mich glücklicherweise nur Lernobjekt um diverse negative Mechanismen und Kriterien zu lernen.
Somit habe ich lediglich am Baume der Erkenntnis gerüttelt und die Früchte eingesammelt,
was mir aber nicht den Eintritt ins (Bio-)Paradies gebracht hat.
Schau daher ab und zu mal rein, reagiere aber nicht mehr auf den normalen Widersinn.
Neue Mutationen des Unsinns reizen mich denn doch zur Gegenrede.
Da ich bei meinen Bio-Pharma-Invest inzwischen weit mehr negative (oder besser nicht (voll) erfüllte) Ergebnisse gesehen habe,
bin ich da vorsichtiger geworden und habe schon Respekt für die,
die sich auskennen (insbesondere im clinical stage Bereich) und hier stark investieren.
Also keinen
Bad Neid.
Schönen Abend
Linkshänder
AEZS war für mich glücklicherweise nur Lernobjekt um diverse negative Mechanismen und Kriterien zu lernen.
Somit habe ich lediglich am Baume der Erkenntnis gerüttelt und die Früchte eingesammelt,
was mir aber nicht den Eintritt ins (Bio-)Paradies gebracht hat.
Schau daher ab und zu mal rein, reagiere aber nicht mehr auf den normalen Widersinn.
Neue Mutationen des Unsinns reizen mich denn doch zur Gegenrede.
Da ich bei meinen Bio-Pharma-Invest inzwischen weit mehr negative (oder besser nicht (voll) erfüllte) Ergebnisse gesehen habe,
bin ich da vorsichtiger geworden und habe schon Respekt für die,
die sich auskennen (insbesondere im clinical stage Bereich) und hier stark investieren.
Also keinen
Bad Neid.
Schönen Abend
Linkshänder
Vorzüge von Langzeit-Growth am Beispiel ANET:
https://www.fool.com/investing/2019/02/22/why-arista-network…
https://www.fool.com/investing/2019/02/22/why-arista-network…
Durchsuchen
